ONCY
ONCOLYTICS BIOTECH INC
$0.8400
-3.45%
$99.8M
No data for this timeframe.
Vol
Market Cap$99.8M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders3 funds
Inst. Value$378.4K
Inst. Activity1 buys / 0 sells
Insider Activity13B / 0S
Insider Net $$258.8K
SEC Reports10
Press Releases1
Recent Activity
Jun 5, 2026
short_volume
Short Volume: ONCY — 67.0% short (0.4M / 0.6M)
Short: 427,270 | Exempt: 1,671 | TRF Vol: 638,059 | Short Ratio: 67.0% | Off-exchange volume (dark p
Jun 2, 2026
SEC
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdo
8-K — Impact 2/10
Jun 1, 2026
SEC
Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates great
8-K — Impact 3/10
Jun 1, 2026
Insider
Kelly Jared sold 755,000 shares
Chief Executive Officer @ $0.00 ($0.00)
Jun 1, 2026
Insider
Aromando Andrew sold 260,000 shares
Chief Business Officer @ $0.00 ($0.00)
Jun 1, 2026
Insider
Look Kirk sold 260,000 shares
Chief Financial Officer @ $0.00 ($0.00)
May 22, 2026
SEC
Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2026, showing pelareo
8-K — Impact 3/10
Inst.
MORGAN STANLEY — DOUBLED
383,346 shares ($536.7K)
Price Targets
$5.02
+500.2% upside
Strong Buy
Current $0.8362
Low $2.91
Median $4.21
High $9.91
6 analysts
$2.91
$9.91
Analyst Ratings
1Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 17, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Aug 13, 2025 | Lake Street | INITIATE | Buy |
| May 21, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 16, 2025 | Jones Trading | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next FY | $-0.36 ▲ +1.3% | $-0.44 — $-0.30 | -4% YoY | 4 |
| Current Q | $-0.07 ▲ +1.6% | $-0.08 — $-0.07 | -5% YoY | 3 |
| Current FY | $-0.35 ▲ +6.8% | $-0.36 — $-0.33 | 17% YoY | 3 |
| Next Q | $-0.08 ▼ -4.3% | $-0.08 — $-0.07 | 45% YoY | 3 |
Latest Reports
NEUTRAL
8-K
2/10
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdo
Jun 2, 2026
NEUTRAL
8-K
3/10
Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates great
Jun 1, 2026
NEUTRAL
Press
4/10
Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showi
May 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $372.8K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $4.7K | — |
| BANK OF AMERICA CORP | $874.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Kelly Jared | A | $0.00 |
| Jun 1, 2026 | Aromando Andrew | A | $0.00 |
| Jun 1, 2026 | Look Kirk | A | $0.00 |
| Jun 1, 2026 | McAdory John | A | $0.00 |
| Jun 1, 2026 | Hagerman Allison | A | $0.00 |
3 institutional holders with $378.4K total value (432,919 shares) as of 2025-Q4. Top holders: MORGAN, WELLS, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 426,518 | $372.8K | 98.5% | DOUBLED +1933.3% |
| 2 | WELLS FARGO & COMPANY/MN | 5,401 | $4.7K | 1.2% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 1,000 | $874.00 | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 18,853 | 383,346 | +1933.3% | $536.7K | 2025-Q3 |
| CITADEL ADVISORS LLC | EXIT | 79,249 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 138,521 | 26,542 | -80.8% | $23.1K | 2024-Q3 |
13 unique insiders with 13 transactions. Net insider value: $258.8K ($258.8K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Kelly Jared | Chief Executive Officer | A | 755,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Aromando Andrew | Chief Business Officer | A | 260,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Look Kirk | Chief Financial Officer | A | 260,000 | $0.00 | $0.00 |
| Jun 1, 2026 | McAdory John Bearden | Chief Operating Officer | A | 145,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Hagerman Allison | Chief Technology Officer | A | 260,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Parsons James T. | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Seizinger Bernd R. | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Heineman Thomas Charles | Chief Medical Officer | A | 260,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Glover Stephen C. | Director | A | 96,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Holtham Angela | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Andrews Patricia S | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Brown Deborah Margaret | Director | A | 30,000 | $0.00 | $0.00 |
| Mar 12, 2026 | Kelly Jared | Chief Executive Officer | BUY | 5,050 | $0.9600 | $4.8K |
| Mar 11, 2026 | Parsons James T. | Director | BUY | 10,000 | $1.03 | $10.3K |
| Feb 12, 2026 | Look Kirk | Chief Financial Officer | BUY | 12,000 | $0.8420 | $10.1K |
| Feb 12, 2026 | Pisano Wayne | Director | BUY | 30,000 | $0.8446 | $25.3K |
| Feb 12, 2026 | Kelly Jared | Chief Executive Officer | BUY | 29,500 | $0.8420 | $24.8K |
| Feb 12, 2026 | Heineman Thomas Charles | Chief Medical Officer | BUY | 12,132 | $0.8270 | $10.0K |
| Feb 12, 2026 | Brown Deborah Margaret | Director | BUY | 25,000 | $0.8496 | $21.2K |
| Feb 12, 2026 | Seizinger Bernd R. | Director | BUY | 40,000 | $0.8466 | $33.9K |
| Feb 12, 2026 | Andrews Patricia S | Director | BUY | 35,400 | $0.8557 | $30.3K |
| Feb 12, 2026 | Hagerman Allison | VP, Product Development | BUY | 10,000 | $0.8298 | $8.3K |
| Feb 11, 2026 | Aromando Andrew | Chief Business Officer | BUY | 29,600 | $0.8587 | $25.4K |
| Feb 11, 2026 | Kelly Jared | Chief Executive Officer | BUY | 5,600 | $0.8360 | $4.7K |
| Feb 11, 2026 | Seizinger Bernd R. | Director | BUY | 60,000 | $0.8265 | $49.6K |
10 SEC filing reports analyzed. Sentiment: 4 bullish, 3 bearish, 0 mixed, 3 neutral. Avg impact: 5.1/10.
NEUTRAL
8-K
2/10
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the pro
Jun 2, 2026
NEUTRAL
8-K
3/10
Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitor
Jun 1, 2026
NEUTRAL
8-K
3/10
Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2
May 22, 2026
BULLISH
8-K
7/10
Oncolytics Biotech announced alignment with the FDA on a randomized controlled pivotal trial design
Apr 27, 2026
BEARISH
424B5
6/10
Oncolytics Biotech is conducting an at-the-market offering of up to $75 million in common stock thro
Apr 6, 2026
BULLISH
8-K
6/10
Oncolytics Biotech announced a scheduled Type C meeting with the FDA on April 16, 2026, to discuss a
Apr 6, 2026
BEARISH
EFFECT
6/10
Oncolytics Biotech's S-3 shelf registration has become effective, allowing the company to issue up t
Apr 6, 2026
BEARISH
S-3
6/10
Oncolytics Biotech filed a shelf registration (S-3) to offer up to $250 million in securities, inclu
Apr 1, 2026
BULLISH
CLUSTER
5/10
Two corporate insiders at Oncolytics Biotech purchased shares in the open market within the past wee
Mar 13, 2026
BULLISH
8-K
7/10
Oncolytics Biotech announced it will prioritize registrational studies in squamous cell anal cancer
Feb 24, 2026
Current analyst consensus: Buy (75% buy). Based on 8 analysts: 1 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.02 mean target
+500.2% upside
Strong Buy (1.83)
$2.91 Low
$9.91 High
| Metric | Value |
|---|---|
| Current Price | $0.8362 |
| Target Low | $2.91 |
| Target Mean | $5.02 |
| Target Median | $4.21 |
| Target High | $9.91 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.83) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next FY 2027-12-31 |
$-0.36 | $-0.44 | $-0.30 | -3.8% | +1.3% | 3↑ 0↓ | $0.0B | 0.0% | 4 |
| Current Q 2026-06-30 |
$-0.07 | $-0.08 | $-0.07 | -4.8% | +1.6% | 3↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.35 | $-0.36 | $-0.33 | 16.6% | +6.8% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.08 | $-0.08 | $-0.07 | 44.5% | -4.3% | 3↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.073 | |
| 7d ago | $-0.073 | -0.000 |
| 30d ago | $-0.074 | +0.001 |
| 60d ago | $-0.069 | -0.004 |
| 90d ago | $-0.069 | -0.004 |
12 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 8 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 17, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 13, 2025 | Lake Street | INITIATE | — | Buy |
| May 21, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 16, 2025 | Jones Trading | DOWNGRADE | Buy | Hold |
| Mar 10, 2025 | Maxim Group | MAINTAIN | Buy | Buy |
| Mar 10, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 10, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 3, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 4, 2024 | Raymond James | INITIATE | — | Outperform |
| Mar 8, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 19, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 4, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 16, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 29, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 23, 2023 | Canaccord Genuity | REITERATE | Buy | Buy |
| Jun 7, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 26, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 24, 2023 | JonesTrading | INITIATE | — | Buy |
| Mar 14, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 6, 2023 | Canaccord Genuity | MAINTAIN | — | Buy |
| Oct 6, 2022 | Maxim Group | INITIATE | — | Buy |
| Feb 17, 2021 | HC Wainwright & Co. | INITIATE | — | Buy |
| May 11, 2020 | RBC Capital | MAINTAIN | — | Outperform |
| Sep 12, 2013 | Needham | INITIATE | — | Buy |
| Mar 4, 2013 | Piper Sandler | INITIATE | — | Overweight |
| Dec 18, 2012 | Bloom Burton & Co. | DOWNGRADE | Buy | Hold |
| Sep 12, 2012 | Bloom Burton & Co. | MAINTAIN | — | Buy |
| Aug 30, 2012 | Stifel | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
short_volume
Short Volume: ONCY — 67.0% short (0.4M / 0.6M)
Short: 427,270 | Exempt: 1,671 | TRF Vol: 638,059 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
other
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.
May 22, 2026
fda
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor g
May 19, 2026
short_volume
Short Volume: ONCY — 67.8% short (0.4M / 0.5M)
Short: 366,538 | Exempt: 9,599 | TRF Vol: 540,780 | Short Ratio: 67.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ONCY — 62.6% short (0.4M / 0.6M)
Short: 350,657 | Exempt: 2,000 | TRF Vol: 560,105 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: ONCY — 59.3% short (0.6M / 1.0M)
Short: 567,495 | Exempt: 42,526 | TRF Vol: 956,546 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
other
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Oncolytics Biotech announced Type C meeting with the FDA aligning on the design of clinical study to support approval of pelareorep in patients with S
Apr 27, 2026
short_volume
Short Volume: ONCY — 63.8% short (2.0M / 3.2M)
Short: 2,025,897 | Exempt: 21,485 | TRF Vol: 3,177,252 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: ONCY — 58.9% short (0.5M / 0.8M)
Short: 462,983 | Exempt: 100 | TRF Vol: 785,922 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: ONCY — 59.5% short (0.5M / 0.9M)
Short: 510,110 | Exempt: 49,117 | TRF Vol: 857,025 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: ONCY — 58.7% short (0.8M / 1.4M)
Short: 813,724 | Exempt: 26,344 | TRF Vol: 1,386,828 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: ONCY — 62.2% short (0.4M / 0.6M)
Short: 350,749 | Exempt: 21,264 | TRF Vol: 563,775 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_volume
Short Volume: ONCY — 70.9% short (0.4M / 0.6M)
Short: 415,211 | Exempt: 15,533 | TRF Vol: 585,893 | Short Ratio: 70.9% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
other
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
<p align="justify">SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech<sup>®</sup> Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”),
Apr 1, 2026
short_volume
Short Volume: ONCY — 68.4% short (0.5M / 0.7M)
Short: 462,135 | Exempt: 11,000 | TRF Vol: 675,179 | Short Ratio: 68.4% | Off-exchange volume (dark pool + OTC)